South & Central America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

Description

List of Tables

The South & Central America glaucoma therapeutics market was valued at US$ 352.85 million in 2023 and is expected to reach US$ 428.75 million by 2031; it is estimated to register a CAGR of 2.5% from 2023 to 2031.

Development of Wearable Technologies Fuels South & Central America Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. n March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

South & Central America Glaucoma Therapeutics Market Overview

The South & Central America glaucoma therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to have a significant market share in this region. Also, it is projected to record the highest growth rate. In Brazil, POAG is the most common type of glaucoma, accounting for ~80% of cases. Developing healthcare facilities, rising prevalence of glaucoma, and growing R&D activities by research organizations in the region are expected to contribute to the rapid growth of the glaucoma therapeutics market. According to an article published in SciELOBrazil in February 2021, glaucoma was the leading cause of blindness in Brazil. By 2030, an estimated 95.4 million people in Brazil will have glaucoma. Numerous ophthalmology conferences are being held in the country, which aid in exploring different technologies in the medical field. In addition, the demand for glaucoma therapeutics is rising due to growing medical tourism in the country. Brazil has multiple Joint Commission International (JCI)-accredited hospitals that meet global standards. These hospitals have advanced medical technology and highly skilled professionals, and they offer various specialties, including ophthalmology, noninvasive surgeries, and cardiology. According to an article published in the VHL Regional Portal in May 2023, a study of patients referred by general ophthalmologists to the clinic for suspected glaucoma at a tertiary public hospital in southern Brazil from March 2016 to December 2018 was conducted. The study, including 135 patients from other countries, concluded that the patients with the normal tension glaucoma had a more advanced stage of the disease at the time of diagnosis. This signifies that patients from developed countries are traveling to developing countries such as Brazil to seek advanced medical diagnoses and treatments offered by the country.

Brazil is experiencing a rise in the geriatric population, which is expected to increase the demand for ophthalmology products. In 2020, the elderly population was 30.1 million, representing ~14.3% of the population. The Brazilian Institute of Geography and Statistics (IBGE) estimates (2019) show that this age group will grow at a rate of 3.6% per year, reaching 73.4 million by 2060, which will be equal to 32.2% of the population. Thus, growing medical tourism and rising geriatric population are expected to propel the market growth during the forecast period.

South & Central America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Glaucoma Therapeutics Market Segmentation

The South & Central America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the South & Central America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the South & Central America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the South & Central America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the South & Central America glaucoma therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the South & Central America glaucoma therapeutics market.

Product Code: BMIRE00031614

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. South & Central America Glaucoma Therapeutics Market - Key Market Dynamics

4.1 Glaucoma Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Mounting Incidence of Glaucoma Disease
- 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
4.3 Market Restraints
- 4.3.1 Medication Regimen Compliance Issues
4.4 Market Opportunities
- 4.4.1 Development of Wearable Technologies
4.5 Future Trends
- 4.5.1 Development of Novel Drug Delivery Methods
4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - South & Central America Analysis

5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
5.2 Glaucoma Therapeutics Market Forecast Analysis

6. South & Central America Glaucoma Therapeutics Market Analysis - by Drug Class

6.1 Beta Blockers
- 6.1.1 Overview
- 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.2 Alpha Adrenergic Agonists
- 6.2.1 Overview
- 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Prostaglandins Analogues
- 6.3.1 Overview
- 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Carbonic Anhydrase Inhibitors
- 6.4.1 Overview
- 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.5 Combination Drugs
- 6.5.1 Overview
- 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. South & Central America Glaucoma Therapeutics Market Analysis - by Indication

7.1 Open Angle Glaucoma
- 7.1.1 Overview
- 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Angle Closure Glaucoma
- 7.2.1 Overview
- 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. South & Central America Glaucoma Therapeutics Market Analysis - by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Retail Pharmacy
- 8.2.1 Overview
- 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Online Pharmacy
- 8.3.1 Overview
- 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. South & Central America Glaucoma Therapeutics Market - Country Analysis

9.1 South & Central America Glaucoma Therapeutics Market Overview
- 9.1.1 South & Central America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
  - 9.1.1.1 South & Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.4 Rest of South & Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.4.1 Rest of South & Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.4.2 Rest of South & Central America: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.4.3 Rest of South & Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

10.1 Growth Strategies in Glaucoma Therapeutics Market
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview

11. Company Profiles

11.1 Alcon AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Bausch & Lomb Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sun Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Thea Pharma Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Santen Pharmaceutical Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms